739360-84-0

Usage

Uses

Used in Organic Synthesis:
(2R,4S)-4-AMINO-1-CBZ-PYRROLIDINE-2-carboxylic acid methyl ester is used as a building block in organic synthesis for the creation of various bioactive molecules. Its unique structure allows for the development of complex organic compounds that can have a range of applications in different fields.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (2R,4S)-4-AMINO-1-CBZ-PYRROLIDINE-2-carboxylic acid methyl ester is utilized as a key intermediate for the synthesis of pharmaceutical agents. Its properties make it suitable for the development of new drugs, potentially leading to advancements in medicinal chemistry and therapeutics.
Used in the Development of New Drugs:
(2R,4S)-4-AMINO-1-CBZ-PYRROLIDINE-2-carboxylic acid methyl ester is employed as a starting material in the development of new drugs due to its stereochemical configuration and functional groups. This allows researchers to explore its potential in creating novel pharmaceutical agents with improved efficacy and selectivity.
Used in the Preparation of Diverse Chemical Structures:
Owing to its versatility and reactivity, (2R,4S)-4-AMINO-1-CBZ-PYRROLIDINE-2-carboxylic acid methyl ester is used in the preparation of a wide array of chemical structures. This makes it an essential component in the synthesis of various compounds for research and industrial applications.

Upstream product

• 113490-74-7 4(S)-azido-N-<(phenylmethoxy)carbonyl>-(S)-proline methyl ester 
• 13504-85-3 (2S,4R)-1-(benzyloxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid 
• 2584-71-6 cis-hydroxy-D-proline 
• 1499-56-5 (R)-4-hydroxy-L-proline ethyl ester 
• 117811-78-6 methyl (2S,4R)-1-benzyloxycarbonyl-4-methanesulfonyloxypyrrolidine-2-carboxylate 
• 64187-48-0 methyl (2S,4R)-1-benzyloxycarbonyl-4-hydroxypyrrolidine-2-carboxylate 
• 1035596-36-1 (2S,4R)-1-benzyl 2-methyl 4-(1,3-dioxoisoindolin-2-yl)pyrrolidine-1,2-dicarboxylate 
• 189215-90-5 1-benzyl 2-methyl (2S,4R)-4-(tert-butoxycarbonylamino)pyrrolidine-1,2-dicarboxylate 
• 189215-87-0 (2S,4S)-4-(4-Nitro-benzoyloxy)-pyrrolidine-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester 
• 189215-88-1 1-benzyl 2-methyl (2S,4S)-4-((methylsulfonyl)oxy)pyrrolidine-1,2-dicarboxylate 
• 57653-35-7 (2S,4S)-4-hydroxypyrrolidine-1,2-dicarboxylic acid 1-benzyl 2-methyl 
• 189215-89-2 (2S,4R)-N-1-(benzyloxycarbonyl)-4-azidoproline methyl ester 
• 51-35-4 4R-4-hydroxyproline 
• 178488-33-0 (2R,4R)-4-Methanesulfonyloxy-pyrrolidine-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester 

Downstream Products

• 1253790-74-7 4S-N⁴(t-Boc)-N₁(Fmoc)-D-amino proline 

Relevant academic research and scientific papers

Spiegelmeric 4R/S-hydroxy/amino-L/D-prolyl collagen peptides: conformation and morphology of self-assembled structures

The primary structure of collagen, the major protein in connective tissue of mammals, comprises of repeating triads [(LPro-LHyp-Gly)n, P1, LHyp being 4R-hydroxy-lProline)] in a single strand that adopts left-handed polyproline II type helix. Three such single stranded helices wind around each another and held together by interchain H-bonds to form right-handed triple helix. This manuscript reports on collagen derived from its mirror image triad [(DPro-DHyp-Gly)n, P2, DHyp being 4S-hydroxy-DProline) and its 4-amino analogue (DPro-DAmp-Gly)n P4, DAmp being 4S-amino-DProline that form corresponding spiegelmeric triplexes. The amino L-collagen peptide (LPro-LAmp-Gly)n P3 and its D-analogue P4 show higher thermal stabilities compared to 4-hydroxy-lProline collagen peptides P1 and P2. The enantiomeric peptide pairs show mirror image CD profiles and identical thermal stability, with ionizable 4-amino group in P3 and P4 imparting pH dependent triplex stability. Upon cold mixing of the L- and D-collagen peptides, different morphological nanostructures arise from inter triplex peptide association. When the peptides are hot mixed (annealed), the inter peptide association occurs via interaction of single stranded peptide chains of opposite handedness leading to networked gel formation in P1 and P2, while the charged peptides P3 and P4 show more ordered nanofibers, different from the enantiomerically pure peptides. The nanocomposites of such chiral hybrid peptides may have not only interesting physicomorphology, but also biological properties that need exploration.

DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE

Provided herein are a dihydropyrimidine compound and use as a medicament, especially application as a medicament used for treating and preventing hepatitis B. Specifically, provided herein is a compound having Formula (I) or (Ia), or a stereisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is use of the compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as a medicament, especially use as a medicament for treating and preventing hepatitis B.

Dihydropyridine compound and application thereof to drugs

The invention relates to a dihydropyridine compound and application of the dihydropyridine compound serving as a drug, in particular to application of the dihydropyridine compound serving as a drug for treating and preventing hepatitis B. Specifically, the invention relates to the compound shown as the general formula (I) or (Ia) (please see the specifications for the general formula (I) or (Ia))or stereoisomers, tautomer, a nitrogen oxide, solvate, metabolites and medically acceptable salt of the compound or a prodrug of the compound, wherein all variables are defined in the specification. The invention further relates to application of the compound shown as the general formula (I) or (Ia) or enantiomers, non-enantiomers, the tautomer, hydrates, the solvate or the medically acceptable salt of the compound serving as drugs, in particular to application of the compound or the enantiomers, the non-enantiomers, the tautomer, the hydrates, the solvate or the medically acceptable salt of the compound serving as the drugs for treating and preventing hepatitis B.

PROLINE DERIVATIVES FOR USE IN THE TREATMENT OF DIABETES

The present invention provides novel heterocyclic compounds and methods of preparing such compounds. The compounds of the invention are useful for palliative, curative or prophylactic treatment of diseases or conditions of diabetes and/or hypertension. This invention also relates to pharmaceutical compositions containing the compounds of the present invention, and methods for palliative, curative or prophylactic treatment of diseases or conditions of diabetes and/or hypertension. The present invention also provides pharmaceutical compositions consisting of the heterocyclic compounds along with one or more dyslipidemic agents, antiobesity agents, anti-hyperglycemic agents, antihypertensive agents and anti-inflammatory agents.

SYNTHESIS OF PYRROLIDINE COMPOUNDS

Provided are methods for the preparation of certain substituted pyrrolidine compounds, forms of (2S, 4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride, and methods for preparing and using these forms.

Discovery and synthesis of HIV integrase inhibitors: Development of potent and orally bioavailable N-methyl pyrimidones

The human immunodeficiency virus type-1 (HIV-1) encodes three enzymes essential for viral replication: a reverse transcriptase, a protease, and an integrase. The latter is responsible for the integration of the viral genome into the human genome and, therefore, represents an attractive target for chemotherapeutic intervention against AIDS. A drug based on this mechanism has not yet been approved. Benzyl-dihydroxypyrimidine-carboxamides were discovered in our laboratories as a novel and metabolically stable class of agents that exhibits potent inhibition of the HIV integrase strand transfer step. Further efforts led to very potent compounds based on the structurally related N-Me pyrimidone scaffold. One of the more interesting compounds in this series is the 2-N-Me-morpholino derivative 27a, which shows a CIC95 of 65 nM in the cell in the presence of serum. The compound has favorable pharmacokinetic properties in three preclinical species and shows no liabilities in several counterscreening assays.

Pyrrolidine carbamate nucleic acids: Synthesis and DNA binding studies

An efficient solid phase synthesis of pyrrolidine carbamate nucleic acids is reported. The protected (2S, 4S)-4-aminopyrrolidine-2-methanol with nucleobases thymine and cytosine attached to the ring nitrogen through an acetyl linker can be activated as ni

Synthesis and evaluation of prolyl carbamate nucleic acids (PrCNA)

Carbamate linked prolyl nucleic acids are obtained in high yield and purity under mild conditions in solution and solid phase. p-Nitrophenylchloroformate is used as the activating reagent for alcohol. Homooligomers of PrCNA do not bind to DNA. The introduction of this modification in PNA sequences destabilizes the triplxes, inspite of enhancement in the base stacking.

Synthesis of new building blocks for peptide nucleic acids containing monomers with variations in the backbone

New PNA monomers containing aminoprolines or pyrrolidines as backbones have been synthesized. Oligomerisation was carried out on a solid support. Resistance to enzymatic degradation was tested.